We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-12.61%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.9B
AUM Growth
-$300M
Cap. Flow
+$207M
Cap. Flow %
7.15%
Top 10 Hldgs %
60.65%
Holding
101
New
14
Increased
15
Reduced
4
Closed
21
Avg Time Held Equity + Options
3.9 quarters
Top 10 Avg Time Held Equity + Options
5.3 quarters
Top 20 Avg Time Held Equity + Options
5 quarters
Avg Time Held Equity only
4 quarters
Top 10 Avg Time Held Equity only
5.3 quarters
Top 20 Avg Time Held Equity only
5 quarters

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$145M
2
ARVN icon
Arvinas
ARVN
+$81.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$58.7M
4
RVMD icon
Revolution Medicines
RVMD
+$58.5M
5
ALLO icon
Allogene Therapeutics
ALLO
+$39.8M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$103M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$41.2M
3
PCVX icon
Vaxcyte
PCVX
+$31.5M
4
BCYC icon
Bicycle Therapeutics
BCYC
+$24M
5
EXEL icon
Exelixis
EXEL
+$19.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.48%
2 Miscellaneous 0.84%
3 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRTA icon
1
Prothena Corp
PRTA
$429M
$315M 10.86%
11,584,280
– –
2018 Q4
14 quarters
APLS icon
2
DELISTED
Apellis Pharmaceuticals
APLS
$234M 8.09%
5,183,431
– –
2021 Q4
2 quarters
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.74B
$215M 7.42%
2,868,145
+798,511
+39% +$58.7M
2022 Q1
1 quarter
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$178M 6.16%
+1,008,628
New +$145M
2022 Q2
0 quarters
LKFT icon
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$178M 6.16%
3,197,500
+1,876
+0.1% +$111K
2021 Q3
3 quarters
ANAB icon
6
AnaptysBio
ANAB
$1.36B
$153M 5.27%
7,521,024
– –
2019 Q4
10 quarters
XNCR icon
7
Xencor
XNCR
$1.75B
$145M 4.99%
5,282,416
+313,660
+6% +$7.74M
2018 Q4
14 quarters
ARVN icon
8
Arvinas
ARVN
$447M
$131M 4.54%
3,123,300
+1,619,371
+108% +$81.3M
2021 Q4
2 quarters
KURA icon
9
Kura Oncology
KURA
$874M
$122M 4.2%
6,638,371
– –
2015 Q4
26 quarters
MORF icon
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$85.7M 2.96%
3,951,566
– –
2019 Q2
12 quarters
ACAD icon
11
Acadia Pharmaceuticals
ACAD
$3.21B
$84.4M 2.91%
5,991,479
– –
2021 Q4
2 quarters
ZLAB icon
12
Zai Lab
ZLAB
$2.59B
$84.3M 2.91%
2,431,885
+208,673
+9% +$7.36M
2022 Q1
1 quarter
RVMD icon
13
Revolution Medicines
RVMD
$40.4B
$83.4M 2.88%
4,278,069
+3,003,972
+236% +$58.5M
2022 Q1
1 quarter
RLAY icon
14
Relay Therapeutics
RLAY
$3.8B
$62.4M 2.15%
3,723,541
+1,432,100
+62% +$30.7M
2020 Q3
7 quarters
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$60M 2.07%
1,975,611
– –
2022 Q1
1 quarter
ALLO icon
16
Allogene Therapeutics
ALLO
$446M
$51.2M 1.77%
+4,488,200
New +$39.8M
2022 Q2
0 quarters
ARGX icon
17
argenx
ARGX
$50.5B
$47.4M 1.63%
125,000
– –
2022 Q1
1 quarter
TSVT icon
18
DELISTED
2seventy bio
TSVT
$46.1M 1.59%
3,495,943
– –
2021 Q4
2 quarters
NUVB icon
19
Nuvation Bio
NUVB
$1.66B
$45M 1.55%
13,896,543
– –
2021 Q1
5 quarters
AVIR icon
20
Atea Pharmaceuticals
AVIR
$399M
$45M 1.55%
6,340,639
– –
2021 Q4
2 quarters
CERE icon
21
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$43.5M 1.5%
1,646,260
– –
2022 Q1
1 quarter
ALEC icon
22
Alector
ALEC
$209M
$41.2M 1.42%
4,056,548
-1,681,900
-29% -$16.8M
2021 Q1
5 quarters
RNAM
23
DELISTED
Avidity Biosciences
RNAM
$40.1M 1.38%
2,759,505
– –
2020 Q2
8 quarters
DSGN icon
24
Design Therapeutics
DSGN
$612M
$36.9M 1.27%
2,634,178
+262,733
+11% +$3.55M
2021 Q1
5 quarters
VYGR icon
25
Voyager Therapeutics
VYGR
$132M
$28.1M 0.97%
4,753,907
+1,196,400
+34% +$8.08M
2021 Q3
3 quarters
1
2 3 4 5

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2022 Portfolio in Review

As of Q2 2022, EcoR1 Capital held 101 positions worth $2.9B, down 9.4% from $3.2B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital deployed $207M of net new capital in Q2 2022, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Alector, an estimated $16.8M trimmed.

  • EcoR1 Capital's largest Q2 2022 buy was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.
  • EcoR1 Capital added most to Arvinas in Q2 2022, an estimated $81.3M increase.
  • EcoR1 Capital's biggest Q2 2022 reduction was Alector, cutting an estimated $16.8M.
  • EcoR1 Capital fully exited Arcus Biosciences in Q2 2022, selling an estimated $103M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $2.9B portfolio in Q2 2022.
  • EcoR1 Capital opened 14 new positions and closed 21 in Q2 2022.
  • EcoR1 Capital's portfolio value fell 9.4% quarter-over-quarter to $2.9B.

Based on EcoR1 Capital's 13F filing for Q2 2022, filed 15 Aug 2022.